-+ 0.00%
-+ 0.00%
-+ 0.00%

KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV) SIGNIFICANTLY IMPROVED EVENT-FREE SURVIVAL, OVERALL SURVIVAL AND PATHOLOGIC COMPLETE RESPONSE RATES FOR CISPLATIN-ELIGIBLE PATIENTS WITH MIBC WHEN GIVEN BEFORE AND AFTER SURGERY

Reuters·12/17/2025 11:45:00

Please log in to view news